All News
ACR20 - Day 4 Report
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Read Article
Tofacitinib for Ankylosing Spondylitis
Investigations on the efficacy and safety of JAK inhibitors as a therapeutic option in the management of AS are increasing.
Read Article
Watch our video on the "Safety of JAKs: Venou Thromboemboic Risk" by Dr. Kevin Winthrop #ACR20
https://t.co/toY1MHo88H https://t.co/FNhrrgkit8
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Roundup! We share the highlights of the virtual #ACR20 meeting.
https://t.co/WUfpsmuX0g https://t.co/uOScYO9LXr
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch our video titled Safety of JAKs: Venous Thromboembolic Risk by Dr. Kevin Winthrop. #ACR20
https://t.co/bKV3gS89Aq
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast out now on our site #ACR20
Mid-Meeting Recap: Psoriatic Arthritis, Gout Patient Outcomes on Low-Dose Steroids, Giant Cell Arteritis Panel Vaccination w/ Shingrix: Does it work for patients on JAKi? Is it safe?
https://t.co/roc1Qjec5R https://t.co/gSkkj2Kl0m
Links:
Dr. John Cush RheumNow ( View Tweet)
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
Janet Pope Janetbirdope ( View Tweet)
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor
-HZ events more common in patients taking 30mg vs 15mg
-HZ more common in UPA vs those taking ADA+MTX & MTX
Abs#2002 #ACR20 @RheumNow
https://t.co/tQ03wBueW5
Mrinalini Dey DrMiniDey ( View Tweet)
Which JAKi will you use after MTX failure? #acr20 @rheumnow
k dao KDAO2011 ( View Tweet)
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Jeffrey Curtis RADoctor ( View Tweet)
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Robert B Chao, MD doctorRBC ( View Tweet)
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors
- Most RA pts on JAKi have sufficient antibody response to HZ vaccine
- Acceptable safety profile
Abs#1997 #ACR20 @RheumNow
https://t.co/8HWAIwOATD
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
Richard Conway RichardPAConway ( View Tweet)
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
Dr. John Cush RheumNow ( View Tweet)
Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
Richard Conway RichardPAConway ( View Tweet)
SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
Eric Dein ejdein1 ( View Tweet)
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
Olga Petryna DrPetryna ( View Tweet)
No need to stop Tofa w/the flu?
👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.
👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.
Abstr#L04 #ACR20 @rheumnow #ACRBest
https://t.co/rZXKRVl7uK
k dao KDAO2011 ( View Tweet)
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
